These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The Impact of Cryopreservation on Hematopoietic Stem Cell Engraftment and Post-transplant Outcome During the COVID-19 Pandemic. Strzelec A; Gawlik-Rzemieniewska N; Klima A; Panek K; Helbig G In Vivo; 2024; 38(3):1271-1277. PubMed ID: 38688614 [TBL] [Abstract][Full Text] [Related]
6. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721 [TBL] [Abstract][Full Text] [Related]
7. Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience. Guo M; Liu J; Clark P; Ahmad S; Patel R; Varela JC; Mori S Int J Hematol; 2023 Mar; 117(3):428-437. PubMed ID: 36378406 [TBL] [Abstract][Full Text] [Related]
8. Impact of Covid 19 pandemic on hematopoietic stem cell transplantation activities: Report from a single center. Giammarco S; Sica S; Metafuni E; Limongiello MA; Valentini CG; Sorà F; Marra JD; Bacigalupo A; Teofili L; Chiusolo P Transfus Apher Sci; 2023 Aug; 62(4):103708. PubMed ID: 37003931 [TBL] [Abstract][Full Text] [Related]
9. Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell products. Wan BA; Lindo L; Mourad YA; Chung S; Forrest D; Kuchenbauer F; Nantel S; Narayanan S; Nevill T; Power M; Rodrigo J; Sanford D; Song K; Stubbins RJ; Sutherland H; Toze CL; White J; Roy C; Hay KA Cytotherapy; 2024 Oct; 26(10):1210-1216. PubMed ID: 38819367 [TBL] [Abstract][Full Text] [Related]
10. Cryopreservation of Growth Factor-Mobilized Peripheral Blood Stem Cells Does Not Compromise Major Outcomes after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. Connelly-Smith L; Gooley T; Roberts L; Mielcarek M; Linenberger M; Petersdorf E; Sandmaier BM; Milano F Transplant Cell Ther; 2023 Nov; 29(11):700.e1-700.e8. PubMed ID: 37659695 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic. Devine SM; Bo-Subait S; Kuxhausen M; Spellman SR; Bupp C; Ahn KW; Stefanski HE; Auletta JJ; Logan BR; Shaw BE Blood Adv; 2023 Oct; 7(19):5982-5993. PubMed ID: 37036959 [TBL] [Abstract][Full Text] [Related]
12. Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products. Auletta JJ; Novakovich JL; Stritesky GL; Newman J; Fridy-Chesser ST; Hailperin K; Devine SM Transplant Cell Ther; 2021 Feb; 27(2):133-141. PubMed ID: 33830022 [TBL] [Abstract][Full Text] [Related]
13. Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program. Farhadfar N; Newman J; Novakovich J; Barten J; Ndifon ET; Oakes J; Cody M; Pham HP; Auletta JJ; Miller JP; Devine SM; Stefanski HE Front Immunol; 2022; 13():937900. PubMed ID: 36203566 [TBL] [Abstract][Full Text] [Related]
14. Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. Bankova AK; Caveney J; Yao B; Ramos TL; Bögeholz J; Heydari K; Diaz N; Jackson ML; Lowsky R; Brown JW; Johnston L; Rezvani AR; Frank MJ; Muffly L; Weng WK; Sidana S; Negrin RS; Miklos DB; Shiraz P; Meyer EH; Shizuru JA; Arai S Transplant Cell Ther; 2022 Apr; 28(4):215.e1-215.e10. PubMed ID: 35042013 [TBL] [Abstract][Full Text] [Related]
15. Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program. Kanda Y; Inoue M; Uchida N; Onishi Y; Kamata R; Kotaki M; Kobayashi R; Tanaka J; Fukuda T; Fujii N; Miyamura K; Mori SI; Mori Y; Morishima Y; Yabe H; Kodera Y Transplant Cell Ther; 2021 Aug; 27(8):664.e1-664.e6. PubMed ID: 33964514 [TBL] [Abstract][Full Text] [Related]
16. Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. Novitzky-Basso I; Remberger M; Chen C; Pasić I; Lam W; Law A; Gerbitz A; Viswabandya A; Lipton JH; Kim DD; Kumar R; Mattsson J; Michelis FV Eur J Haematol; 2022 Jan; 108(1):61-72. PubMed ID: 34606661 [TBL] [Abstract][Full Text] [Related]
18. Transplantation of allogeneic cryopreserved hematopoietic cell grafts during the Covid-19 pandemic: A National Marrow Donor Program perspective. Devine SM Am J Hematol; 2021 Feb; 96(2):169-171. PubMed ID: 33206414 [No Abstract] [Full Text] [Related]
19. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic? Fernandez-Sojo J; Azqueta C; Valdivia E; Martorell L; Medina-Boronat L; Martínez-Llonch N; Torrents S; Codinach M; Canals C; Elorza I; Parody R; Martino R; Trabazo M; Díaz de Heredia C; Ferra C; Valcárcel D; Linares M; Ancochea Á; García-Rey E; García-Muñoz N; Medina L; Castillo N; Carreras E; Villa J; Querol S Bone Marrow Transplant; 2021 Oct; 56(10):2489-2496. PubMed ID: 34127808 [TBL] [Abstract][Full Text] [Related]
20. Pros and Cons of Cryopreserving Allogeneic Stem Cell Products. Valentini CG; Pellegrino C; Teofili L Cells; 2024 Mar; 13(6):. PubMed ID: 38534396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]